Alphamab Oncology (stock code: 9966.HK) announced that the preclinical data on two novel bispecific antibody-drug conjugates (ADCs) JSKN021 and JSKN022 were presented as posters at the 2025 American ...

Announcing a new article publication for BIO Integration journal. Bladder cancer (BLCA) is one of the most common malignancies and the second most frequent urogenital tract tumor.

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Many patent applicants currently face difficulty in obtaining antibody claims because of written description and enablement ...

A team of scientists has uncovered the remarkable potential of a human antibody, mAb 3A6, in fighting Ebola virus infections.

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced that the U.S. Food and Drug Administration (FDA) has ...

The US Food and Drug Administration (FDA) has approved an investigational new drug (IND) application from Aclaris ...

Allen Guo, CEO "We are excited to present our pre-clinical findings at the AACR, showcasing the significant potential of our CD3 agonistic single-domain antibody," said Allen Guo, CEO.

Allen Guo, CEO "We are excited to present our pre-clinical findings at the AACR, showcasing the significant potential of our CD3 agonistic single-domain antibody," said Allen Guo, CEO. "This platform ...